Potential application of lutetium-177-labeled prostate-specific membrane antigen-617 radioligand therapy for metastatic castration-resistant prostate cancer in a limited resource environment: Initial clinical experience after 2 years - Assadi, M; Rezaei, S; Jafari, E (World Journal of Nuclear Medicine, 2020)